Medical Condition News

RSS

Green tea consumption increases number of 'regulatory T cells', prevents autoimmune disease

One of the beneficial compounds found in green tea has a powerful ability to increase the number of "regulatory T cells" that play a key role in immune function and suppression of autoimmune disease, according to new research in the Linus Pauling Institute at Oregon State University.

3 Jun 2011

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.

3 Jun 2011

Elevated CRP levels predict poor prognosis of breast cancer

Levels of C-reactive protein (CRP) are increased in response to acute inflammation, infection and tissue damage. There are also reports that CRP levels are elevated because of cancer.

3 Jun 2011

FDA approves Mylan's ANDA for Venlafaxine HCl ER Capsules to treat depressive, anxiety disorder

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Venlafaxine Hydrochloride Extended-release Capsules, 37.5 mg (base), 75 mg (base) and 150 mg (base), the generic version of Wyeth's Effexor XR Capsules, which are used in the treatment of major depressive disorder and social anxiety disorder.

3 Jun 2011

Mild brain injury tracked using special MRI technique

According to a new study there may be an explanation of why some military personnel exposed to blasts have symptoms of brain injury even though their CT and MRI scans look normal.

2 Jun 2011

Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome

Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 3 study to evaluate the effects of STX209 on social impairment in adolescents and adults with fragile X syndrome.

2 Jun 2011

Clovis Oncology, Roche partner to develop in vitro PCR-based diagnostic test for NSCLC

Clovis Oncology, Inc. and Roche, announced today that they have entered into an agreement to develop an in vitro PCR based companion diagnostic test.

2 Jun 2011

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that one of its clinical trial advisers will present results from an ElectroImmunotherapy clinical trial for melanoma at the 2011 American Society of Clinical Oncology Annual Meeting to be held June 4-8 at McCormick Place, Chicago, IL.

2 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

Microscopic worms in space

A space flight by millions of microscopic worms could help us overcome the numerous threats posed to human health by space travel. The Caenorhabditis elegans (C. elegans) have also given experts an insight into how to block muscle degradation in the sick and elderly.

2 Jun 2011

People with individual health coverage have highest cancer costs

One of every seven cancer patients spends more than 20 percent of his income on health care and insurance, according to a new study from federal researchers.

2 Jun 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.

2 Jun 2011

Transcendental Meditation reduces symptoms of PTSD in veterans just within 8 weeks

Veterans of the Iraq/Afghanistan wars showed a 50 percent reduction in their symptoms of post-traumatic stress disorder (PTSD) after just eight weeks of practicing the stress-reducing Transcendental Meditation technique, according to a pilot study published in the June 2011 issue of Military Medicine.

2 Jun 2011

WHO warns of tobacco dangers on World No Tobacco Day

"Tobacco will kill nearly six million people this year, including 600,000 non-smokers, because governments are not doing enough to persuade people to quit or protect others from second-hand smoke, the World Health Organization (WHO) said on Tuesday," which was observed as World No Tobacco Day, Reuters/Toronto Sun reports.

2 Jun 2011

Diffusion tensor imaging detects brain abnormalities in U.S. military personnel with mild traumatic brain injury

An advanced imaging technique has revealed that some U.S. military personnel with mild blast-related traumatic brain injuries have abnormalities in the brain that have not been seen with other types of imaging.

2 Jun 2011

Insecure people experience more conflict in sexual life

People who feel secure in in their relationship with their partner have a more satisfactory sex life and are more able to be sensitive in the affection they give. However, people who are insecure, who tend towards anxiety or avoidance and are compulsive or controlling in their affection experience more conflict in their sexual desire and are less happy in their relationships, according to a study by the University of the Basque Country.

2 Jun 2011

Individuals with hair loss can benefit from Sequencing technique

Hair loss remains an important distressing side effect for certain patients and individuals and although there are certainly more critical health issues there is no doubt that loss of hair is a stressful experience for men and women.

2 Jun 2011

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Symphogen announced today that Phase 2 data will be presented from an open-label, multi-center clinical trial evaluating the safety and tolerability of rozrolimupab in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP) at the 16th Congress of the European Hematology Association meeting in London, UK on June 10 from 5:45 to 7:00 PM.

2 Jun 2011

WHO/IARC say mobile phone use may increase risk of certain brain cancers

Mobile phone use "may increase the risk of certain types of brain cancer in humans," therefore "consumers should consider ways of reducing their exposure," a WHO/International Agency for Research on Cancer (IARC) working group concluded on Tuesday, Reuters reports.

2 Jun 2011

Cell phone use poses no cancer risk, says JunkScience publisher

Today's media hoopla about the World Health Organization classifying cell phone use as "possibly carcinogenic" is much ado about nothing. The studies the WHO relies on are weak association studies that have zero reliability.

2 Jun 2011

Medical Condition News

Green tea consumption increases number of 'regulatory T cells', prevents autoimmune disease

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Elevated CRP levels predict poor prognosis of breast cancer

FDA approves Mylan's ANDA for Venlafaxine HCl ER Capsules to treat depressive, anxiety disorder

Mild brain injury tracked using special MRI technique

Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome

Clovis Oncology, Roche partner to develop in vitro PCR-based diagnostic test for NSCLC

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Microscopic worms in space

People with individual health coverage have highest cancer costs

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Transcendental Meditation reduces symptoms of PTSD in veterans just within 8 weeks

WHO warns of tobacco dangers on World No Tobacco Day

Diffusion tensor imaging detects brain abnormalities in U.S. military personnel with mild traumatic brain injury

Insecure people experience more conflict in sexual life

Individuals with hair loss can benefit from Sequencing technique

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

WHO/IARC say mobile phone use may increase risk of certain brain cancers

Cell phone use poses no cancer risk, says JunkScience publisher

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Latest News